

# 30<sup>TH</sup> ECNP CONGRESS | 2-5 SEPTEMBER 2017

# PARIS

*For the science and treatment of disorders of the brain*



**CONGRESS AT A GLANCE**

<http://2017.ecnp.eu>

**WELCOME TO THE 30<sup>TH</sup> ECNP CONGRESS!**




Username: ECNP2017  
Password: ECNP2017

**DOWNLOAD THE ECNP APP**



*Available for  
Apple and  
Android*

## FLOOR PLANS



## SATURDAY 2 SEPTEMBER

### 12.15-14.00 Satellite symposia

C.01 | THINC-it™: from mood to cognition R. Lam, R. McIntyre, B. Baune **Bleu**

*Educational financial support provided by H. Lundbeck A/S*

C.10 | Continuous treatment in schizophrenia: addressing the controversies I. Bitter, H. Nasrallah, J. Olivares **Bordeaux**

*Educational financial support provided by Janssen Pharmaceutical Companies*

### 14.00-14.45 ECNP patient session

ES.01 | Terror attack and treatment – what should and what should not be done in the 'Golden Hours' **Havane**

*A. Gibert, F. Ducrocq, J. Zohar, F. Rudetzki*

### 14.45-16.30 Satellite symposia

C.03 | Improvement of functional outcomes in schizophrenia – the role of long-acting injectable antipsychotics **Bordeaux**

*A. Malla, J. Bridges, R. Emsley, S. Heres*

*Educational financial support provided by Otsuka Pharmaceutical Europe Ltd. & H. Lundbeck A/S*

C.04 | Functional consequences of major depressive disorder **Bleu**

*J. Jaeger, L. Hammer-Helmich, C. Bowie*

*Educational financial support provided by H. Lundbeck A/S*

### 16.50-18.30 Symposia & Educational update session

**PR** S.01 | Elucidating the genetic architecture of psychiatric disease **Maillot**

*T. Pers, T. Bourgeron, A. Hinney, T. Kato*

**TR** S.02 | Aggression in conduct disorder is associated with altered top-down cortical processing mechanisms: a translational perspective J. Glennon, E. Viding, A. Zuddas, S. Tremmery **Room 352AB**

**CR** S.03 | Role of oxytocin in social behaviour and stress coping **Bleu**

*O. Bosch, M. Olff, V. Frokjaer, R. Hurlmann*

**CT** S.04 | Rapid onset of action in the treatment of depression: evidence and mechanisms **Grand Amphitheatre**

*L. Monteggia, P. Zanos, T. Rantamäki, T. Svensson*

**PR** S.05 | Neuronal autophagy: concepts and treatment options **Havane**

*D. Rubinsztein, C. Cavadas, S. Issazadeh-Navikas, T. Rein*

**ET** E.01 | EPA educational session – New insights in the negative symptoms of schizophrenia **Bordeaux**

*A. Mucci, S. Dollfus*

### 18.45-20.00 Keynote session

KL.01 | Targeting glutamate in psychiatric disease J. Krystal **Grand Amphitheatre**

### 20.00-21.00 Welcome reception **Level 2**

*Participants are invited to the welcome reception to meet and interact with colleagues.*

*A drink and a small bite will be served.*

## SUNDAY 3 SEPTEMBER

### 07.45-08.45 Brainstorming sessions

- BS.01 | Clinical implementation of chemogenetics, a revolutionary brain directed treatment *R. Adan, D. Kullmann* **Room 341**  
BS.02 |  $\alpha 7$  Nicotine acetylcholine receptor ( $\alpha 7$ nAChR) negative allosteric modulators: next generation anxiolytics **Room 342B**  
*C. Lowry, J. Mikkelsen*  
BS.03 | Prevention of mental disorders: the role of treatment in pregnancy *M. Galbally, I. Jones* **Room 343**

### 09.00-17.00 Exhibition

#### 09.00-10.40 Symposia & Educational update session

- PR** S.06 | Novel approaches to cocaine addiction *V. Pascoli, O. Engmann, K. Ersche, M. Mameli* **Havane**  
**TR** S.07 | Cognitive dysfunction across psychiatric disorders **Grand Amphitheatre**  
*P. Amminger, B. Sahakian, B. Cuthbert, D. Nieman*  
**CR** S.08 | Can genetic and epigenetic variation predict and mediate therapy response in anxiety disorders? **Bleu**  
*K. Schruers, A. Erhardt, S. Roberts, K. Domschke*  
**CT** S.09 | The role of brain connectivity in affective and psychotic disorders: implications for treatment **Maillot**  
*A. Meyer-Lindenberg, E. Opmeer, O. Howes, M. Marcelis*  
**CR** S.10 | TNM symposium – New avenues in ADHD research: from pathophysiology to phenotypic expression and treatment  
*H. Larsson, S. Kooij, P. Asherson, T. Banaschewski* **Room 352AB**  
**ET** E.02 | Advances in the understanding and treatment of borderline personality disorder *B. Stanley* **Bordeaux**

#### 09.00-11.00 Expert science exchange

- CE.01 | Appropriate treatment choice in recent-onset schizophrenia: applicability and usefulness of a novel e-health tool  
*R. Emsley, J. Kane, C. Correll* **Room 241**  
*Organised by Otsuka Pharmaceutical Europe Ltd and H. Lundbeck A/S*

#### 10.40-11.15 Poster viewing **Poster area** / **Travel award ceremony** **Poster area (podium)** / **Coffee break** **Poster area and exhibition**

#### 11.15-12.00 Plenary lecture

- PL.01 | Endophenotypes in schizophrenia *R. Freedman* **Grand Amphitheatre**

#### 12.00-14.00 Lunch **Poster area and exhibition**

#### 12.00-14.00 Nomenclature session

- NS.01 | Why and how psychotropic nomenclature was changed: presenting the NbN app – focus on the paediatric **Bordeaux**  
*C. Arango, S. Wilson, D. Nutt, J. Zohar, P. Blier*

#### 12.15-13.45 Poster session **Poster area**

#### 12.15-12.45 Rapid-fire poster session **Poster area (podium)**

#### 13.00-13.15 Poster award ceremony **Poster area (podium)**

#### 13.15-13.45 Career development session

- CD.01 | Abstract writing: how to pitch your results concisely and convincingly *K. Ersche* **Poster area (podium)**

#### Top paper sessions TP.01 | Highlights in neuropsychopharmacology *F. Drago* **Room 341**

TP.02 | Highlights in child and adolescent disorders *M. Parellada* **Room 342B**

#### 14.00-14.45 Plenary lecture PL.02 | Multimodal neuroimaging in neurodegenerative diseases *G. Chételat* **Grand Amphitheatre**

#### 14.45-15.00 Coffee break **Poster area and exhibition**

#### 15.00-16.40 Symposia & Educational update session

- PR** S.11 | MicroRNAs in affective disorders **Havane**  
*J. Radulovic, L. Hommers, J. Lopez, A. Forstner*  
**TR** S.12 | New findings in applied neuroscience research I **Room 352AB**  
*B. Lassus, P. Tornese, A. Forero, T. Roelofs, E. Loureiro-Campos, R. Saha, R. Mongredien, B. Coimbra*  
**CR** S.13 | New psychoactive substances: 'legal highs', cognitive lows? **Grand Amphitheatre**  
*M. Torrens, M. Baumann, D. Wood, J. Ramaekers*  
**CT** S.14 | Relapse and relapse prevention following electroconvulsive therapy for depression: where are we now? **Bleu**  
*P. Sienaert, E. Verwijk, D. McLoughlin, C. Kellner*  
**CT** S.15 | The role of resilience in schizophrenia **Maillot**  
*J. Kane, A. Hofer, H. Uchida, T. Wykes*  
**ET** E.03 | Hoarding disorder: update on neurobiology, diagnosis and treatment **Bordeaux**  
*D. Mataix-Cols, D. Cath*

#### 15.00-17.00 Expert science exchange

- CE.02 | Great debates on optimizing treatment for MDD *Roger McIntyre, Stephen M. Stahl* **Room 241**  
*Organised by Pfizer Inc.*

#### 17.15-19.00 Satellite symposia

- C.05 | Treatment-resistant schizophrenia (TRS) – clinical presentation, neurobiology and treatment considerations **Bordeaux**  
*J. Kane, O. Howes, J. MacCabe*  
*Educational financial support provided by H. Lundbeck A/S*  
C.07 | The depressed patient's perspective in achieving remission **Havane**  
*K. Demyttenaere, M. Hopwood, G. Hajak*  
*Educational financial support provided by SERVIER*  
C.08 | Treatment of schizophrenia negative symptoms in the light of current therapeutic possibilities **Maillot**  
*S. Galderisi, W. Fleischhacker, A. Cutler*  
*Educational financial support provided by Gedeon Richter Plc. & RECORDATI S.p.A*

## MONDAY 4 SEPTEMBER

### 07.45-08.45 Brainstorming sessions

- BS.04 | New technologies for reducing placebo response and improving signal detection in CNS clinical trials **Room 341**  
*M. Detke, J. Rabinowitz*
- BS.05 | The 'stressed' hippocampus as target for treatment of comorbid epilepsy and depression **Room 342B**  
*L. D'Alessio, E. de Kloet*
- BS.06 | Breaking the link between insomnia and depression *T. Paunio, E. van Someren* **Room 343**

### 09.00-17.00 Exhibition

#### 09.00-10.40 Symposia & Educational update session

- PR** S.16 | New findings in applied neuroscience research II **Room 352AB**  
*H. Sanghani, J. Barut, C. Dioli, M. Kaczmarczyk, G. Schoretsanitis, I. Elbau, J. van Leeuwen, R. Das*
- TR** S.17 | Sex differences at the intersection of stress, fear and depression **Grand Amphitheatre**  
*O. Almeida, C. Dalla, L. Garcia-Segura, G. Hodes*
- CR** S.18 | Behavioural addictions: diagnosis, co-morbidity and neurobiology **Maillot**  
*M. Potenza, A. Weinstein, F. Thibaut, V. Voon*
- CT** S.19 | What is the impact of physical exercise interventions in schizophrenia? **Bleu**  
*H. Pol, B. Malchow, W. Honer, J. Hietala*
- S.20 | Regulatory spotlight session – Strategies for the development of medicines for autism spectrum disorders **Havane**  
*J. Buitelaar, S. Lenton, M. Tome, L. Ham*
- ET** E.04 | How do genetic studies advance understanding and treatment of psychiatric disease? **Bordeaux**  
*J. Hall, F. Degenhardt*

#### 09.00-11.00 Expert science exchange

- CE.03 | From cognitive function to daily functioning in depression *A. Serretti, J. Harrison, T. Greer, J. Haro, E. Vieta, D. Cha* **Room 241**  
*Organised by H. Lundbeck A/S*

#### 10.40-11.15 Poster viewing **Poster area** / Travel award ceremony **Poster area (podium)** / Coffee break **Poster area and exhibition**

#### 11.15-12.00 Plenary lecture

- PL.03 | Brain Prize Award lecture – Synaptic plasticity in health and disease *G. Collingridge* **Grand Amphitheatre**

#### 12.00-14.00 Lunch **Poster area and exhibition**

#### 12.15-13.45 Poster session **Poster area**

#### 12.15-13.15 General Assembly of ECNP members **Havane**

#### 12.15-12.45 Rapid-fire poster session **Poster area (podium)**

#### 13.00-13.15 Poster award ceremony **Poster area (podium)**

#### 13.15-13.45 Career development session

- CD.02 | Life beyond academia or the clinic: a career in industry *T. Steckler* **Poster area (podium)**

#### Top paper sessions

- TP.03 | Highlights in addiction *P. Gorwood* **Room 341**
- TP.04 | Highlights in experimental medicine *J. Deakin* **Room 342B**

#### 14.00-14.45 Plenary lecture

- PL.04 | ECNP Neuropsychopharmacology Award lecture – A journey into serotonin: 40 years of discoveries and surprises  
*M. Hamon* **Grand Amphitheatre**

#### 14.45-15.00 Coffee break **Poster area and exhibition**

#### 15.00-16.40 Symposia & Educational update session

- PR** S.21 | The stressed genome in affective disorders: a novel target for pharmacological intervention? **Bleu**  
*N. Provençal, C. Pariante, M. Riva, J. Reul*
- TR** S.22 | GABA dysfunction in the pathogenesis of schizophrenia: from bench to clinic **Room 352AB**  
*A. Grace, F. Benes, G. Ende, G. Modinos*
- CR** S.23 | New tools to understand and seek success at youth suicide prevention **Maillot**  
*J. Mann, D. Wasserman, G. Zalsman, H. Christensen, H. Wilcox*
- CT** S.24 | Use of human brain implants to interpret brain activity and clinical applications to neurological disorders  
*M. VanSteensel, B. Jarosiewicz, C. De Hemptinne, T. Skarpaas* **Grand Amphitheatre**
- CR** S.25 | Reward processing as cross-cutting phenomenon in psychiatric classifications **Havane**  
*A. Heinz, M. Luijten, E. Jimenez, A. Scheres*
- ET** E.05 | Tackling the challenge of treatment resistant depression **Bordeaux**  
*H. McAllister-Williams, S. Kayser*

#### 15.00-17.00 Expert science exchange

- CE.04 | Addressing comorbid adult ADHD in psychiatric patients *Y. Ginsberg, L. Klassen, A. Rostain* **Room 241**  
*Organised by Shire International GmbH*

#### 17.15-19.00 Satellite symposia

- C.02 | Rethinking the spectrum of mood disorders: implications for diagnosis and management *A. Young, P. Haddad* **Maillot**  
*Educational financial support provided by Sunovion Pharmaceuticals and Sumitomo Dainippon Pharma*
- C.09 | Can we improve functioning in our patients with schizophrenia? The potential role of D2 partial agonists **Bordeaux**  
*S. Brissos, G. Mattingly, O. Agid, C. Correll*  
*Educational financial support provided by Otsuka Pharmaceutical Development & Commercialization Inc. & H. Lundbeck A/S*

## 07.45-08.45 Brainstorming sessions

- BS.07 | An effective alcohol hangover treatment: friend or foe? *D. Nutt, J. Verster* **Room 341**
- BS.08 | How do smartphones and other ubiquitous technologies change patient care paradigms in movement disorders?  
*V. Legrand, S. Van Sint Jan* **Room 342B**
- BS.09 | Future perspective for treatment of bipolar disorder: stratification *I. Grande, G. Hasler* **Room 343**

## 09.00-17.00 Exhibition

### 09.00-10.40 Symposia & Educational update session

- PR** S.26 | Contribution of epistasis (gene-gene interactions) to the clinical and quantitative risk for the schizophrenia phenotype  
*S. Williams, J. Waddington, K. Nicodemus, A. Bertolino* **Havane**
- TR** S.27 | The role of stressful life events on shaping the adult brain and genome toward psychopathology **Bleu**  
*B. Etain, A. Cattaneo, M. Aas, C. Anacker*
- CR** S.28 | TNM symposium – Digital applications in bipolar disorders: opportunities, risks and ethical implications  
*K. Saunders, M. Faurholt-Jepsen, D. Hidalgo-Mazzei, M. Bauer* **Grand Amphitheatre**
- CT** S.29 | Neurofeedback in ADHD: evidence from different modalities **Maillot**  
*M. Arns, D. Brandeis, B. Barth, K. Rubia*
- TR** S.30 | Myelination from cells to brain networks: a core mechanism of plasticity and connectivity **Room 352AB**  
*M. Kole, T. Sheldrick-Michel, K. Whitaker, S. Frangou*
- ET** E.06 | Exercise and psychiatric disease: should patients take the challenge? **Bordeaux**  
*H. Van Praag*

### 09.00-11.00 Expert science exchange

- CE.05 | Redefining treatment goals for difficult to treat depression *S. Aaronson, P. Sienaert* **Room 241**  
*Organised by LivaNova*

### 10.40-11.15 Poster viewing **Poster area** / Travel award ceremony **Poster area (podium)** / Coffee break **Poster area and exhibition**

### 11.15-12.00 Plenary lecture

- PL.05 | From genes to clinical phenotype in ADHD across the lifespan *B. Franke* **Grand Amphitheatre**

### 12.00-14.00 Lunch **Poster area and exhibition**

### 12.15-13.45 Poster session **Poster area**

### 12.15-12.45 Rapid-fire poster session **Poster area (podium)**

### 13.00-13.15 Poster award ceremony **Poster area (podium)**

### 13.15-13.45 Career development session

- CD.03 | How to get funding: writing a strong grant or fellowship application *P. Svenningsson* **Poster area (podium)**

### Top paper sessions

- TP.05 | Highlights in anorexia nervosa – focus on translational research *D. Viltart* **Room 341**
- TP.06 | Highlights in psychotic disorders *P. Steullet* **Room 342B**

### 14.00-14.45 Plenary lecture

- PL.06 | Cognitive and functional remediation in affective disorders *A. Martinez-Aran* **Grand Amphitheatre**

### 14.45-15.00 Coffee break **Poster area and exhibition**

### 15.00-16.40 Symposia & Educational update session

- PR** S.31 | TNM symposium – Common mechanisms and therapeutic avenues for Down syndrome and other genetic developmental disorders *R. Kadosh, V. Faundez, M. Dierssen, B. Bardoni* **Havane**
- TR** S.32 | New approaches to psychiatric drug development **Room 352AB**  
*J. van Gerven, C. Tamminga, C. Harmer, M. Kas*
- CR** S.33 | Causes and consequences of inflammation in bipolar disorder **Grand Amphitheatre**  
*L. Capuron, A. Andreazza, D. Bond, F. Benedetti*
- CT** S.34 | Sexual side effects of antidepressant and antipsychotic drugs: clinical challenge and underlying mechanisms **Bleu**  
*A. Montejo Gonzalez, A. Clayton, C. Broberger, D. Naber*
- CT** S.35 | Melatonin receptors in neuropsychopharmacology: a preclinical and clinical update **Maillot**  
*S. Comai, G. Gobbi, V. Vengeliene, N. Zisapel*
- ET** E.07 | Synthetic cannabinoids: a growing problem? **Bordeaux**  
*G. Shoval, L. Fattore*